Aurobindo Pharma Limited
All news and filings related to Aurobindo Pharma Limited.
View all news & filings- Medium impact
Aurobindo's Acrotech Biopharma Launches ADQUEY™ in US, Establishes Dermatology Business
Aurobindo Pharma's subsidiary, Acrotech Biopharma, launched ADQUEY™ (difamilast 1%) ointment in the U.S. for atopic dermatitis. This marks Acrotech's entry into the U.S. dermatology market, supported by a newly established dedicated dermatology business unit. The market is valued at approximately US$ 1.3 billion.
Read the summary - Low impact
Aurobindo Pharma fined ₹2.56 Crore plus interest and penalty by GST authority
The Appellate Joint Commissioner confirmed a demand for reversal of alleged excess ITC of ₹2.56 Crore, plus ₹1.78 Crore in interest and a ₹25.64 Lakh penalty. The total disputed amount is ₹4.60 Crore. Aurobindo Pharma plans to appeal the order, stating no material financial or operational impact.
Read the summary - Low impact
Aurobindo Pharma Closes Trading Window from Oct 1 for Q2 FY27 Results
Aurobindo Pharma will close its trading window from October 1, 2026, until 48 hours after the Q2 FY27 results declaration. This affects designated persons, promoters, directors, KMPs, employees, and their relatives. The board meeting date for results will be announced later.
Read the summary - Low impact
Aurobindo Pharma to Participate in JP Morgan Healthcare Trip on Sep 24
Aurobindo Pharma Limited officials will attend the JP Morgan Healthcare Trip in Hyderabad on September 24, 2026. The group meeting is scheduled from 2:30 PM to 3:30 PM IST. No unpublished price sensitive information will be disclosed.
Read the summary - Medium impact
Aurobindo Pharma Subsidiary Apitoria Unit-II Completes US FDA Inspection
Aurobindo Pharma's subsidiary, Apitoria Pharma's Unit-II, completed a US FDA inspection from Sep 7-15, 2026. The inspection resulted in one procedural observation, to which the company will respond within the timeline. Aurobindo remains committed to quality and compliance.
Read the summary - Medium impact
Aurobindo Pharma Receives USFDA Final Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
Aurobindo Pharma received USFDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol (40 mcg and 80 mcg). This is the company's first MDI product, strengthening its respiratory therapy portfolio. The US market for the product was estimated at $301 million. Production will be at its North Carolina facility.
Read the summary - Low impact
Aurobindo Pharma: Step-down subsidiary invests USD 1 Million in A1 Biochem USA Inc
Aurobindo Pharma's step-down subsidiary, A1 Biochem Labs (India) Private Limited, invested USD 1,000,000 (₹8.3 Crore) in A1 Biochem USA Inc. on September 11, 2026. This move supports the Contract Research and Development services business as part of the A1 Biochem Group acquisition.
Read the summary - Medium impact
Aurobindo Pharma subsidiary Unit-IV completes US FDA inspection with zero observations
Aurobindo Pharma's subsidiary, Apitoria Pharma Private Limited, completed a US FDA inspection at its Unit-IV API manufacturing facility. The inspection, held from September 07 to September 11, 2026, concluded with zero observations, highlighting the company's commitment to quality and compliance.
Read the summary - Low impact
AUROPHARMA to Participate in J.P. Morgan India Investor Conference on Sep 22
Aurobindo Pharma Limited officials will attend the J. P. Morgan India Investor Conference in Mumbai on September 22, 2026. The company will engage in one-on-one and group meetings. No unpublished price-sensitive information will be disclosed.
Read the summary - Low impact
Aurobindo Pharma to Participate in Bank of America Asia Pacific Conference on Sep 21
Aurobindo Pharma Limited will participate in the Bank of America 2026 Asia Pacific Conference on September 21, 2026, in Hong Kong. Company officials will hold one-on-one and group meetings. No unpublished price-sensitive information will be disclosed.
Read the summary - Low impact
Aurobindo Pharma to Participate in Emkay Global Group Meeting on Sep 17
Aurobindo Pharma officials will participate in a group meeting organized by Emkay Global. The meeting is scheduled for September 17, 2026, in Hyderabad. No unpublished price-sensitive information will be discussed.
Read the summary - Low impact
Aurobindo Pharma to Participate in Kotak Healthcare Forum 2026 on Sep 18
Aurobindo Pharma Limited officials will attend the Kotak Healthcare Forum 2026 in Mumbai on September 18, 2026. The event includes one-on-one and group meetings. No unpublished price sensitive information will be disclosed.
Read the summary - Low impact
Aurobindo Pharma to Participate in ICICI Securities Investor Meeting on Sep 17
Aurobindo Pharma Limited will participate in an investor meeting hosted by ICICI Securities on September 17, 2026. The group meeting is scheduled from 2:30 PM to 3:30 PM IST in Hyderabad. No unpublished price-sensitive information will be disclosed.
Read the summary - Low impact
Aurobindo Pharma Publishes Newspaper Notice for Share Transfer to IEPF
Aurobindo Pharma published a notice regarding the transfer of equity shares to IEPF. Separately, BPL Limited and SecureKloud Technologies have announced their AGMs on September 25, 2026, with remote e-voting periods from September 21-24 and September 22-24, respectively. The cut-off date for voting rights for both is September 18, 2026.
Read the summary - Low impact
Aurobindo Pharma Subsidiary Incorporates New Wholly Owned Subsidiary 'Avogent Lifesciences'
Aurobindo Pharma's subsidiary, Apitoria Pharma, has incorporated a new wholly owned subsidiary, Avogent Lifesciences Private Limited. The new entity, incorporated on August 31, 2026, will focus on manufacturing and marketing operations in India and abroad. The incorporation involved an initial cash investment of ₹5 crore.
Read the summary - Medium impact
Aurobindo Pharma subsidiary launches generic Advair Diskus in US
Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US. This is the first product from the company's inhalation pipeline to be commercialized in the US market. The product is available in two strengths for treating asthma and COPD.
Read the summary - Low impact
Aurobindo Pharma Subsidiary Unit-VI Clears US FDA Inspection with Procedural Observations
Aurobindo Pharma's subsidiary, Apitoria Pharma, completed a US FDA inspection at its Unit-VI API manufacturing facility. The inspection, held from August 24-28, 2026, concluded with three procedural observations. The company will respond to the FDA within the given timeline.
Read the summary - Low impact
Aurobindo Pharma AGM: All resolutions passed with overwhelming majority
Aurobindo Pharma's 39th AGM on August 27, 2026, saw all resolutions passed with high majority. Key approvals included financial statements for FY26, interim dividend of ₹4 per share, director reappointments, and secretarial auditor appointment. Shareholder turnout was strong, with overwhelming support for all proposals.
Read the summary - Low impact
Aurobindo Pharma Holds 39th AGM on Aug 27, 2026; Transactions Include Dividend Confirmation
Aurobindo Pharma's 39th AGM was held on August 27, 2026. Key decisions included adopting FY26 financial statements and confirming a ₹4 interim dividend. Directors K. Nithyananda Reddy and M. Madan Mohan Reddy were reappointed. Voting results will be announced within two working days.
Read the summary - Low impact
Aurobindo Pharma to Participate in Goldman Sachs Asia Leaders Conference in Hong Kong
Aurobindo Pharma Limited will participate in the Goldman Sachs Asia Leaders Conference in Hong Kong from September 1-2, 2026. Company officials will attend one-on-one and group meetings. No unpublished price-sensitive information will be disclosed.
Read the summary - Low impact
AUROPHARMA to Participate in Elara India Dialogue 2026 Investor Meet on Sep 1
Aurobindo Pharma Limited officials will attend the ASHWAMEDH – Elara India Dialogue 2026 in Mumbai on September 1, 2026. The event will include one-on-one and group meetings. No unpublished price-sensitive information will be discussed.
Read the summary - Low impact
Aurobindo Pharma Subsidiary Lannett Company LLC US FDA Inspection Concludes
Lannett Company LLC, a subsidiary of Aurobindo Pharma, completed a US FDA inspection from August 17-21, 2026. The inspection resulted in four procedural observations. Aurobindo Pharma will respond to the FDA within the stipulated timeline and is committed to maintaining compliance standards.
Read the summary - Medium impact
Aurobindo Pharma Subsidiary Clears US FDA Inspection with One Observation
Aurobindo Pharma's subsidiary, AuroPeptides Ltd., successfully completed a US FDA inspection from August 17-21, 2026. The inspection resulted in only one observation related to facility and equipment maintenance, with no issues concerning data integrity or GMP compliance. Corrective actions have been initiated.
Read the summary - Medium impact
Aurobindo Pharma's US FDA Raleigh Plant Classified VAI, Inspection Closed
Aurobindo Pharma's US FDA Raleigh Plant inspection has concluded with a Voluntary Action Indicated (VAI) classification. The facility manufactures inhalers, dermatology, and transdermal products. This VAI status allows pending applications for inhalers and other dosage forms to proceed with USFDA review.
Read the summary - Low impact
Aurobindo Pharma to Participate in Motilal Oswal Investor Conference on Aug 19
Aurobindo Pharma Limited will participate in the Motilal Oswal 22nd Annual Global Investor Conference on August 19, 2026, in Mumbai. Company officials will hold one-on-one and group meetings. No unpublished price-sensitive information will be disclosed.
Read the summary - Medium impact
Aurobindo Pharma Subsidiary Receives US FDA Warning Letter for Unit I
Eugia Pharma Specialities Ltd., a subsidiary of Aurobindo Pharma, received a US FDA Warning Letter for Unit I. This facility contributes about 2% to the group's revenue. Existing US supplies remain unaffected. The company is working with the FDA to enhance compliance.
Read the summary - Low impact
Aurobindo Pharma Announces Special Window for Physical Share Transfer Requests
Aurobindo Pharma Limited has opened a special window for re-lodging transfer requests of physical shares. The notice was published on August 7, 2026. This initiative aims to facilitate shareholders holding physical shares.
Read the summary - Low impact
Aurobindo Pharma to participate in Nuvama India Conference 2026 in Singapore & Hong Kong
Aurobindo Pharma Limited will participate in the Nuvama India Conference 2026 in Singapore & Hong Kong from August 11-13, 2026. Meetings will be in-person and group formats. No unpublished price sensitive information will be discussed.
Read the summary - Medium impact
Aurobindo Pharma Board Approves Merger of Step-Down Subsidiaries
Aurobindo Pharma's Board approved a merger of its step-down subsidiaries, Eugia Steriles and Eugia SEZ, into Eugia Pharma Specialities. All entities manufacture injectable pharmaceuticals. The merger aims to simplify group structure and reduce costs. For FY26, Eugia Pharma had ₹272.59 crore turnover, Eugia Steriles ₹0.63 crore, and Eugia SEZ ₹48.74 crore.
Read the summary - High impact
Aurobindo Pharma Q1FY27 Revenue Up 16.3% to ₹9,150 Cr; Net Profit Rises 25.2% to ₹1,032 Cr
Aurobindo Pharma reported Q1FY27 consolidated revenue of ₹9,150 crore, up 16.3% YoY. Net profit rose 25.2% to ₹1,032 crore. US revenue grew 8.1% to ₹3,770 crore, Europe revenue increased 25.6% to ₹2,937 crore. The company received USFDA approval for 10 products and generated USD 98 million in free cash flow. An earnings call is scheduled for August 6, 2026.
Read the summary - High impact
Aurobindo Pharma Q1FY27 Revenue Up 16.3% to ₹9,150 Cr; Net Profit Rises 25.2%
Aurobindo Pharma reported Q1FY27 revenue of ₹9,150 Cr, up 16.3% YoY, and net profit of ₹1,032 Cr, up 25.2% YoY. The company launched 10 products in the US and generated US$98 million in free cash flow. CuraTeQ Biologics filed Denosumab with EMA and is preparing for U.S. FDA filings.
Read the summary - Medium impact
Aurobindo Pharma Q1 FY27 Results: Profit Up, Approves Merger Scheme
Aurobindo Pharma reported Q1 FY27 results with standalone profit after tax at ₹7,372.2 million and consolidated profit after tax at ₹10,320.3 million. The Board approved a scheme of amalgamation for merging three subsidiaries with Eugia Pharma Specialities Limited.
Read the summary - Low impact
Aurobindo Pharma Announces 39th AGM on Aug 27, 2026, via VC/OAVM
Aurobindo Pharma Limited will hold its 39th AGM on August 27, 2026, via Video Conferencing. Remote e-voting is open from August 24 to August 26, 2026. The cut-off date for voting eligibility is August 20, 2026. The Register of Members will be closed from August 26-27, 2026.
Read the summary - Low impact
Aurobindo Pharma Announces 39th AGM on Aug 27, 2026, and E-voting Details
Aurobindo Pharma Limited will hold its 39th AGM on August 27, 2026, via VC/OAVM. E-voting is scheduled from August 24-26, 2026, with a cut-off date of August 20, 2026. The Integrated Annual Report for FY25-26 is available online.
Read the summary - Low impact
Aurobindo Pharma Announces 39th AGM on Aug 27, 2026, to Consider FY26 Results & Dividend
Aurobindo Pharma will hold its 39th AGM on August 27, 2026, via VC/OAVM. The agenda includes adopting FY26 audited financial statements (standalone & consolidated) and confirming an interim dividend of ₹4 per share. Directors K. Nithyananda Reddy and M. Madan Mohan Reddy are proposed for re-appointment. Secretarial Auditor to be appointed for five years.
Read the summary - Low impact
Aurobindo Pharma Announces 39th AGM on August 27, 2026
Aurobindo Pharma Limited will hold its 39th Annual General Meeting (AGM) on August 27, 2026. The meeting will be conducted via video conference. Notices were published on July 30, 2026.
Read the summary - Low impact
Aurobindo Pharma Announces 39th AGM on Aug 27, 2026, via VC/OAVM
Aurobindo Pharma Limited will hold its 39th AGM on August 27, 2026, via VC/OAVM. The Register of Members and Share Transfer Books will be closed from August 26 to August 27, 2026, for the AGM.
Read the summary - Low impact
Aurobindo Pharma Schedules Q1FY27 Earnings Call for August 6, 2026
Aurobindo Pharma Limited will hold an Earnings Call on August 6, 2026, at 8:30 AM IST to discuss unaudited financial results for Q1FY27. The presentation will be available on the company website post-announcement. Pre-registration is required for the Zoom call.
Read the summary - Medium impact
Aurobindo Pharma signs non-exclusive voluntary license with MSD for generic alimatravir
Aurobindo Pharma has signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply generic alimatravir in 129 Low- & Middle-Income Countries. This royalty-free agreement aims to expand access to HIV prevention therapies globally, subject to regulatory approvals.
Read the summary - Medium impact
Aurobindo Pharma subsidiary acquires 80% stake in A1 Biochem for USD 17 Million
Aurobindo Pharma's subsidiary, Apitoria Pharma, will acquire an 80% stake in A1 Biochem Group's Contract Research Services business for USD 17 million. The acquisition aims to establish a CRDMO platform, enhancing Aurobindo's API business. A1 Biochem Group had a turnover of INR 1,024.42 million in FY2025-26. The deal is expected to close within 90-120 days.
Read the summary - Medium impact
Aurobindo Pharma Subsidiary's Biosimilars Facility Gets ANVISA Approval
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received ANVISA approval for its biosimilars manufacturing facility in Hyderabad. The approval follows a successful GMP inspection covering API and sterile product manufacturing, strengthening the company's position in Latin American markets.
Read the summary - Medium impact
Aurobindo Pharma Incorporates Wholly Owned Subsidiary PT Auro Pharm Indonesia
Aurobindo Pharma Limited has incorporated a new wholly owned subsidiary, PT Auro Pharm Indonesia, in Indonesia for manufacturing operations. The initial share capital subscribed is IDR 20,000,000,000 (approximately ₹109 crore). This move is aimed at expanding the company's manufacturing footprint.
Read the summary - Low impact
Aurobindo Pharma: Certificate Filed for Dematerialization/Rematerialization Qtr Ended June 30, 2026
Aurobindo Pharma Limited filed a certificate for the quarter ended June 30, 2026. The company confirmed that details of securities dematerialized/rematerialized were furnished to stock exchanges as per SEBI regulations. KFin Technologies Limited provided the confirmation.
Read the summary - Low impact
Aurobindo Pharma completes transfer of domestic formulations business to subsidiary
Aurobindo Pharma Limited has completed the transfer of its domestic branded generic pharmaceutical formulations business to its wholly-owned subsidiary, Auropharm Limited. The business operations officially transitioned to Auropharm Limited effective July 1, 2026, as per the Business Transfer Agreement.
Read the summary - High impact
Aurobindo Pharma Completes Acquisition of Lannett Company, Inc.
Aurobindo Pharma USA Inc. has completed the acquisition of Lannett Company, Inc., effective June 29, 2026. Lannett will now operate as Lannett Company LLC. The acquisition adds over 400 employees to APUSA's workforce.
Read the summary - Medium impact
Aurobindo Pharma Subsidiary's US FDA Inspection Concludes with 2 Observations
Aurobindo Pharma's subsidiary, Auroactive Pharma, underwent a US FDA inspection from June 22-26, 2026. The inspection concluded with 2 observations, to which the company will respond. No financial or operational impact is expected.
Read the summary - High impact
Aurobindo Pharma USA gets FTC nod to acquire Lannett for $250 million
Aurobindo Pharma USA has received FTC approval to acquire Lannett Company for $250 million. The deal, expected to close by June 2026, will expand Aurobindo's product offerings and U.S. manufacturing capacity. The acquisition is anticipated to be immediately accretive to earnings and create long-term value.
Read the summary - Medium impact
Aurobindo Pharma Subsidiary Eugia Steriles Completes US FDA PAI with 5 Observations
Aurobindo Pharma's stepdown subsidiary, Eugia Steriles, completed a US FDA PAI with 5 observations. The inspection occurred from June 10-19, 2026. The company will respond within the stipulated time. No financial or operational impact is expected.
Read the summary - Low impact
Aurobindo Pharma Promoters Disclose No New Share Encumbrances
Aurobindo Pharma's promoters, including K. Nithyananda Reddy, have declared no new share encumbrances for the financial year ended March 31, 2026. This confirms previous disclosures. The announcement lists promoter holdings, with RPR SONS ADVISORS PRIVATE LIMITED and MRS.P.SUNEELA RANI jointly holding 33.50%. Total promoter group holding is 51.82%.
Read the summary - Medium impact
Aurobindo Pharma USA Inc. receives FTC approval for Lannett acquisition.
Aurobindo Pharma USA Inc. has secured FTC approval for its acquisition of Lannett Company LLC. The transaction is expected to close by the end of June 2026. This marks a significant step in Aurobindo Pharma's strategic growth initiatives.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio